Skip to content

Fertility Study of Women With Chronic Inflammatory Rheumatism

Fertility Study of Women With Chronic Inflammatory Rheumatism

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03452735
Acronym
FERTIRHUM
Enrollment
2900
Registered
2018-03-02
Start date
2018-07-16
Completion date
2019-07-31
Last updated
2018-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing Spondylitis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Chronic Juvenile Arthritis

Keywords

Chronic inflammatory rheumatism, Fertility, Procreation

Brief summary

Etiopathogenesis of Chronic inflammatory rheumatisms (CIR) includes genetic, autoimmune and environmental factors. Their impact on the quality of life is important, leading to a sometimes severe disability. Thus they are likely to affect female fertility through several mechanisms, including autoimmune since the association between immunity and fertility has already been demonstrated in other autoimmune diseases. This study wants to evaluate and compare the birth rate between CIR and control group.

Detailed description

Data collection will be carried out using a questionnaire submitted to women in charge of the rheumatology department of the University Hospital of Toulouse and having agreed to participate: * women with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis or Chronic juvenile arthritis for the chronic inflammatory rheumatism group * women with a mechanical rheumatic pathology for the control group The primary endpoint was birth rate after spontaneous or induced pregnancy in patients who attempted to procreate, in the CIR group and in the control group.

Interventions

Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patient with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Chronic juvenile arthritis, Chronic Inflammatory Rheumatism * Patient diagnosed before the age of 40 * Patient having given her no opposition to her participation in research * For the control group: patient not suffering from chronic inflammatory rheumatism, having consulted in Rheumatology for a mechanical pathology

Exclusion criteria

* Patient\> 40 years old at the time of diagnosis * Patient with insufficient medical data (treatments)

Design outcomes

Primary

MeasureTime frameDescription
Birth rate after spontaneous or induced pregnancyOne dayBirth rate after spontaneous or induced pregnancy in women who have tried to procreate in the chronic inflammatory rheumatism group and in the control group.

Secondary

MeasureTime frameDescription
Design timeOne dayDesign time in the CIR group and in the control group
Birth rate according to the treatments usedOne dayBirth rate in the CIR group according to the treatments used
Rates of ectopic pregnancy, early or late spontaneous miscarriageone dayRates of ectopic pregnancy, early or late spontaneous miscarriage, early or late pregnancy, children born dead, preterm birth in the CIR group and in the control group
Rates of desire for pregnancyOne dayRates of desire for pregnancy and study of the reasons for this lack of desire for pregnancy in the CIR group and in the control group
Rates of sexual dysfunctionOne dayRates of sexual dysfunction in the CIR group and in the control group
Birth rate according to the activity of the diseaseOne dayBirth rate in the CIR group according to the activity of the disease

Countries

France

Contacts

Primary ContactJean Parinaud, MD
parinaud.j@chu-toulouse.fr5 67 77 11 02
Backup ContactIsabelle Olivier, PhD
olivier.i@chu-toulouse.fr5 61 77 70 51

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026